19 September 2014 - 19 September 2014 - Danish Novo Nordisk (CPH:NOVO-B) said Friday that the European Commission (EC) had approved Xultophy (IDegLira) as a therapy of adults with Type 2 diabetes mellitus.

Xultophy is the intended trade name for IDegLira, the first once-daily single injection combination of Tresiba (insulin degludec) and Victoza (liraglutide), developed as therapies of Type 2 diabetes.

The medication was authorised in Switzerland last week.

Novo Nordisk plans to launch Xultophy in the first European countries in H1 2015.